Macrogenics to participate in upcoming investor conference

Rockville, md, jan. 08, 2024 (globe newswire) -- macrogenics, inc. (nasdaq: mgnx), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the company's management will participate in the following upcoming investor conference:
MGNX Ratings Summary
MGNX Quant Ranking